NCT06617013Recruiting
GERD in Children With Cystic Fibrosis
Characteristics of Gastroesophageal Reflux in Children With Cystic Fibrosis
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 25 Sept 2024
- Start date
- 23 Oct 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Duke University
- Diseases
- Cystic fibrosis
- NCT number
- NCT06617013
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 23 Oct 2024 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of severe GERD per gastroenterology diagnosis and documentation
Other
- Declining to participate in the study or sign consent
- GSAS score \>80
Who the study is looking for
- Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
- Signed consent
Age in the registry: 2 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Hospital Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.